Blood tests could predict melanoma treatment success
NCT ID NCT07584291
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim to develop a model that predicts how well a patient responds to therapy. The goal is to enable personalized monitoring and treatment strategies for melanoma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACRAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing Hospital, Air Force Medical University
RECRUITINGXi'an, Shaanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer light up hidden cancers?
- E-Learning could sharpen Doctors' eye for skin cancer
- Can a new drug tame advanced solid tumors?
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Which High-Tech camera is better at spotting skin cancer?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.